NewsBenzingaNervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028 NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028 Benzinga 2026.10.12 11:17 (GMT+0) Open on Benzinga Other news Top Wall Street Forecasters Revamp TJX Expectations Ahead Of Q3 Earnings Trump Reportedly Traded Over $97 Million Worth of Nvidia Stock in 2 Years — Elizabeth Warren Wants Congress to Force Him to ‘Divest’ Hafnia Q3 EPS $0.34, Inline, Sales $417.361M Beat $291.583M Estimate Kevin O’Leary Warns Anthropic IPO Investors To ‘Understand’ What They’re Betting On: ‘May Not Make Money Until 2030’ Nebius Shares Jump After Hours as Nvidia’s Strong Quarterly Numbers Lift AI Infrastructure Stocks Reported Earlier, 'Salesforce Has Started Cutting More Jobs, Internal Messages Show' - Business Insider
Trump Reportedly Traded Over $97 Million Worth of Nvidia Stock in 2 Years — Elizabeth Warren Wants Congress to Force Him to ‘Divest’
Kevin O’Leary Warns Anthropic IPO Investors To ‘Understand’ What They’re Betting On: ‘May Not Make Money Until 2030’
Reported Earlier, 'Salesforce Has Started Cutting More Jobs, Internal Messages Show' - Business Insider